All In Biotech

Drug Trial Radar · NCT06188702

S095035 as a Single Agent and in Combination in Adult Participants With Advanced or Metastatic Solid Tumors With Deletion of MTAP

A Phase 1/2, Open-label, Multicenter Clinical Trial Investigating the Safety, Tolerability, Pharmacokinetics, and Antineoplastic Activity of S095035 (MAT2A Inhibitor) as a Single Agent and in Combination in Adult Participants With Advanced or Metastatic Solid Tumors With Homozygous Deletion of MTAP

Last checked: Nov 19, 2026Latest source record: Oct 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

61

Actual

Start

Apr 29, 2024

Primary completion

May 1, 2027

Study completion May 1, 2027

Sponsor

Lead sponsor
Servier Bio-Innovation LLCIndustry
Sponsor type
Industry
Collaborators
Institut de Recherches Internationales Servier; Tango Therapeutics, Inc.
First posted
Jan 3, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a first-in-human Phase 1/2, multicenter, open-label study of S095035 as single-agent, or in combination with TNG462 in adult participants with advanced or metastatic solid tumors with homozygous deletion of MTAP who have failed to respond to or have progressed after at least 1 prior treatment regimen, and for whom additional effective standard treatment is not available. S095035 is an oral methionine adenosyltransferase 2A \[MAT2A\] inhibitor. TNG462 is a protein arginine N-methyltransferase 5 \[PRMT5\] inhibitor.

Conditions

  • MTAP-deleted Solid Tumors

Interventions

  • S095035Drug

    S095035 will be taken orally every day in 28-day cycles.

  • TNG462Drug

    TNG462 will be taken orally every day in 28-day cycles.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Dose limiting toxicities (DLTs)Time frame: Through cycle 1 (each cycle is 28 days)
  2. Total number of adverse events (AEs)Time frame: Through the Safety Follow-up Visit (until 30 days after the last dose of study treatment) approximately 5 years
  3. Total number of serious adverse events (SAEs)Time frame: Through the Safety Follow-up Visit (until 30 days after the last dose of study treatment) approximately 5 years
  4. Objective response rate (ORR)Time frame: Through the end of the study (approximately 5 years)

Locations

20 sites in 7 countries. Site status is shown where the registry gives one.

  • Lake Mary Cancer Center - Florida Cancer Specialists & Research Institute

    Lake Mary, Florida

  • Community Health Network

    Indianapolis, Indiana

  • Taylor Cancer Research Center

    Maumee, Ohio

  • SCRI Oncology Partners

    Nashville, Tennessee

  • NEXT Oncology

    Austin, Texas

  • Townsville University Hospital

    Douglas, Australia

  • Royal Hobart Hospital

    Hobart, Australia

  • Scientia Clinical Research

    Randwick, New South Wales, Australia

  • The Alfred

    Prahran, Victoria, Australia

  • Institut Bergonié

    Bordeaux, France

  • Centre Georges-François Leclerc

    Dijon, France

  • Universitätsklinikum Ulm

    Ulm, Germany

  • Istituto Europeo Di Oncologia

    Milan, Italy

  • Instituto Clinico Humanitas Irccs

    Rozzano, Italy

  • Policlinico G.B. Rossi A.O.U.I. Di Verona

    Verona, Italy

  • Aichi Cancer Center

    Aichi, Japan

  • National Hospital Organization Shikoku Cancer Center

    Ehime, Japan

  • The Cancer Institute Hospital of JFCR

    Tokyo, Japan

  • Hospital Universitario Fundación Jiménez Díaz

    Madrid, Spain

  • Start Madrid Group - Hm Ciocc

    Madrid, Spain

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.